Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics
March 11, 2024 – Drug Discovery – DUB inhibitors, Nanna Therapeutics, Ubiquigent, drug discovery
Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics
11 March 2024 — Dundee, UK — Ubiquigent, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Nanna Therapeutics. Under the terms of the agreement, Ubiquigent will provide Nanna with access to its deubiquitylase (DUB) focused drug discovery platform to support the development of novel therapeutics for human disease targets selected by Nanna.
The DUB enzymes regulate ubiquitination in the ubiquitin-proteasome system (UPS). Dysregulation of DUB activity is implicated in many human diseases, highlighting their importance and promise for the development of novel therapeutics.
Ubiquigent is the partner chosen by many leading industry and academic organisations for their drug discovery programmes in the fields of protein degradation, stabilisation and cellular signalling. Ubiquigent has an established specialised drug discovery platform and long-standing expertise in the exploitation of the DUBs for therapeutic benefit. The platform can be applied to support the development of DUB inhibitors, DUB-targeting PROTACs, and DUBTACs across any therapeutic area.
Jason Mundin, CEO of Ubiquigent, commented: “We are delighted to enter this latest agreement and look forward to supporting the team at Nanna Therapeutics. Our platform was established to support those seeking to modulate DUB activity for therapeutic benefit and has been used by a long list of global partners which we are very pleased to add Nanna Therapeutics to.”
To learn more about Ubiquigent’s discovery and development platform, please visit https://www.ubiquigent.com/platform.
About Ubiquigent
Founded 15 years ago, Ubiquigent has an unrivalled track record and unique range of specialist services focused on the exploitation of the DUB enzymes and ubiquitin-proteasome system (UPS) to create new therapeutics for areas of high unmet medical need. In addition to supporting clients worldwide, Ubiquigent has an internal pipeline of drug discovery programmes and is developing a strong IP portfolio encompassing DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs) and DUB-targeting Chimeras (DUBTACs) for subsequent commercialisation via partnerships and out-licensing agreements. The company benefits from high calibre backing, including from IP Group PLC, Scottish Enterprise, the UK Medical Research Council (MRC) and the University of Dundee, Scotland. Based in a state-of-the-art facility located near the University of Dundee, it sits at the centre of a range of highly relevant additional scientific expertise and capabilities. Visit: www.ubiquigent.com.
About Nanna Therapeutics
Nanna Therapeutics is a small molecule focused therapeutics subsidiary of Astellas, a Japanese global pharmaceutical company. Nanna Therapeutics, is a Cambridge, UK-based biotech, acquired in 2020, and Mitobridge is a Boston, US-based biotech acquired by Astellas in 2018. Nanna and Mitobridge together comprise the Mitobridge Division, a US- and UK-based research engine of Astellas reporting to the Astellas chief scientific officer, focused on the application of engineered small-molecule Drug Discovery. Visit: www.nannatherapeutics.com.
